Understanding how aflatoxin causes DNA damage and affects liver cancer development
Role of Aflatoxin-induced DNA Damage Formation and Repair in Hepatic Mutagenesis
['FUNDING_OTHER'] · UNIVERSITY OF GEORGIA · NIH-10450055
This study looks at how a harmful substance called aflatoxin, which comes from certain molds, can damage DNA in the liver and how this damage might lead to liver cancer, especially when combined with viral infections like hepatitis B and C, to help find ways to reduce cancer risk.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF GEORGIA (nih funded) |
| Locations | 1 site (ATHENS, UNITED STATES) |
| Trial ID | NIH-10450055 on ClinicalTrials.gov |
What this research studies
This research investigates the impact of aflatoxin, a toxin produced by certain fungi, on DNA damage and repair processes in the liver. It focuses on how chronic exposure to aflatoxin B1, combined with viral infections like hepatitis B and C, contributes to liver cancer. By using a combination of biochemical, genetic, and computational methods, the study aims to uncover the mechanisms behind DNA damage formation and repair efficiency related to aflatoxin. This knowledge could help identify risk factors and potential interventions for liver cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of aflatoxin exposure or chronic hepatitis infections who are at risk for liver cancer.
Not a fit: Patients who do not have a history of aflatoxin exposure or liver disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and prevention strategies for liver cancer caused by aflatoxin exposure.
How similar studies have performed: Previous research has shown that understanding DNA damage and repair mechanisms can lead to significant advancements in cancer prevention and treatment, indicating that this approach has potential for success.
Where this research is happening
ATHENS, UNITED STATES
- UNIVERSITY OF GEORGIA — ATHENS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LI, WENTAO — UNIVERSITY OF GEORGIA
- Study coordinator: LI, WENTAO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer, Cancer Causing Agents